Form 4: Intra-Cellular Therapies Executive Exercises Options and Sells Shares

Mark Neumann, EVP and Chief Commercial Officer of Intra-Cellular Therapies, exercised stock options and sold shares on August 16, 2024.

Summary

• On August 16, 2024, Mark Neumann, the EVP, Chief Commercial Officer of Intra-Cellular Therapies, Inc., exercised options to purchase 18,714 shares of common stock at a price of $36.89.
• Following the exercise, Neumann sold 18,714 shares at a weighted average price of $75.08, with prices ranging from $75.00 to $75.25.
• After these transactions, Neumann directly owns 29,700 shares of Intra-Cellular Therapies, Inc.

Sentiment

Score: 5

Explanation: This is a neutral reporting of an executive's stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

Executive stock option exercises and share sales are common occurrences in publicly traded companies and are closely monitored by investors for insights into management's perspective on the company's future prospects. This transaction is a routine disclosure.

Comparison to Industry Standards

• Executive compensation packages often include stock options to align management's interests with those of shareholders.
• The exercise and sale of shares are typical components of these packages.
• Similar transactions are regularly reported by executives at comparable pharmaceutical companies.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• Shareholders may view the transaction as a routine part of executive compensation.

Key Dates